X4 Pharmaceuticals, Inc (XFOR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, X4 Pharmaceuticals, Inc reported revenue of $35.11M, up 1273.2% from the prior year. The company ran a net loss, with a net margin of -225.6%. It held $290.46M in total assets against $104.17M in total liabilities.
Key ratios (FY2025)
-247.4%
Operating margin
-225.6%
Net margin
-42.5%
Return on equity
+1273.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.11M | $2.56M | $0 | $0 | $0 | $3.00M | $0 | $0 | — | — |
| Cost of Revenue | $5.76M | $797.0K | $0 | $0 | — | — | — | — | — | — |
| Operating Income | -$86.88M | -$36.40M | -$107.52M | -$87.57M | -$85.11M | -$59.87M | -$51.70M | -$29.09M | -$22.25M | -$24.35M |
| Net Income | -$79.20M | -$37.45M | -$101.17M | -$93.87M | -$88.70M | -$62.13M | -$52.81M | -$33.28M | -$21.99M | -$22.98M |
| EPS (Diluted) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 | $-3.09 | — | — | — | — |
| Total Assets | $290.46M | $146.45M | $147.26M | $155.59M | $117.18M | $122.87M | $160.70M | $9.94M | $81.25M | — |
| Total Liabilities | $104.17M | $124.30M | $96.16M | $81.53M | $52.76M | $50.07M | $31.48M | $21.62M | $22.55M | — |
| Shareholders' Equity | $186.29M | $22.15M | $51.10M | $74.05M | $64.41M | $72.80M | $129.22M | -$77.09M | -$44.55M | -$23.05M |
| Cash & Equivalents | $217.05M | $55.70M | $99.22M | $121.72M | $81.79M | $78.71M | $126.18M | $8.13M | $26.68M | $15.16M |
| Operating Cash Flow | -$85.62M | -$130.90M | -$96.51M | -$77.10M | -$70.91M | -$58.82M | -$48.05M | -$25.42M | -$21.31M | -$21.64M |
| Capital Expenditures | $0 | $326.0K | $60.0K | $103.0K | $615.0K | $1.36M | $174.0K | $0 | $378.0K | $73.0K |
| Shares Outstanding | 90.91M | 5.70M | 167.43M | 121.67M | 28.13M | 16.31M | 16.13M | 351.7K | 14.29M | — |